The Effectiveness of Glycosaminoglycans in Peripheral Vascular Disease Therapy: A Clinical and Experimental Trial

Thirty patients suffering from peripheral vascular disease (stage–II according to Fontaine) were included in a double-blind study aimed at assessing the efficacy of a high-dose glycosaminoglycan (GAG) (Sulodexide) both in terms of laboratory parameters, such as lipid metabolism and blood coagulation components, and instrumental procedures (strain-gauge plethysmography). Compared with the fifteen control patients (treated with placebo), the fifteen patients treated with Sulodexide showed a signficant decrease in blood triglycerides and fibrinogen as well as a significantly increased HDL-cholesterol, and positive instrumental changes: at the end of treatment Peak and Rest Flow values – and consequently also Winsor's index – were significantly increased only in patients treated with Sulodexide.

Download Full-text

Safety of picotamide, an antiplatelet agent, in an 18-month, double-blind, placebo-controlled, multicenter trial in 2304 patients with peripheral vascular disease

Current Therapeutic Research ◽

10.1016/s0011-393x(05)80624-1 ◽

1993 ◽

Vol 54 (1) ◽

pp. 111-121 ◽

Cited By ~ 4

Author(s):

F. Violi ◽

A. Longoni ◽

M. Maderna ◽

C. Castiglioni ◽

F. Balsano

Keyword(s):

Vascular Disease ◽

Peripheral Vascular Disease ◽

Antiplatelet Agent ◽

Multicenter Trial ◽

Peripheral Vascular ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group.

Circulation ◽

10.1161/01.cir.87.5.1563 ◽

1993 ◽

Vol 87 (5) ◽

pp. 1563-1569 ◽

Cited By ~ 62

Author(s):

F Balsano ◽

F Violi

Keyword(s):

Vascular Disease ◽

Peripheral Vascular Disease ◽

Controlled Study ◽

Peripheral Vascular ◽

Clinical Progression ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Lowering of Plasma Viscosity by the Oral Administration of the Glycosaminoglycan Sulodexide in Patients with Peripheral Vascular Disease

Journal of International Medical Research ◽

10.1177/030006059202000106 ◽

1992 ◽

Vol 20 (1) ◽

pp. 45-53 ◽

Cited By ~ 16

Author(s):

M Lunetta ◽

T Salanitri

Keyword(s):

Oral Administration ◽

Vascular Disease ◽

Peripheral Vascular Disease ◽

Whole Blood ◽

Plasma Viscosity ◽

Lower Limbs ◽

Plasma Fibrinogen ◽

Controlled Study ◽

Peripheral Vascular ◽

Double Blind

The aim of the double-blind, crossover, placebo-controlled study was to evaluate whether oral administration of sulodexide, a medium molecular weight glycosaminoglycan, had an effect on whole blood, plasma and serum viscosity, and/or plasma fibrinogen concentrations. The drug was administered orally at a dose of 500 lipoproteinlipase releasing units twice daily for 1 month to two groups of 20 patients with peripheral vascular disease; one group was administered a placebo–drug sequence and the other a drug–placebo sequence. Orally administered sulodexide had a marked effect on plasma viscosity and on plasma fibrinogen concentrations, whereas there were no effects on whole blood viscosity. No significant side-effects were observed. The fact that sulodexide was highly effective, even after oral administration, suggests it may be useful for the treatment of patients with atheromatous vascular diseases of the lower limbs requiring chronic therapy.

Download Full-text

Effects of a Single I.V. Dose of Nicergoline on Haemorrheological and Haemodynamic Parameters in Peripheral Vascular Disease. A Double-Blind, Cross-over Study

Proof of Therapeutical Effectiveness of Nootropic and Vasoactive Drugs ◽

10.1007/978-3-642-70786-5_12 ◽

1986 ◽

pp. 159-168

Author(s):

T. Di Perri ◽

M. Guerrini ◽

R. Cappelli ◽

A. Acciavatti ◽

D. Peera-Galli ◽

...

Keyword(s):

Vascular Disease ◽

Peripheral Vascular Disease ◽

Peripheral Vascular ◽

Double Blind ◽

Haemodynamic Parameters

Download Full-text

Comparison of the Efficacy and Safety of Daily Dosages of 6 mg and 20 mg Dihydroergocristine in the Treatment of Chronic Cerebro-Vascular Disease

Journal of International Medical Research ◽

10.1177/030006059502300401 ◽

1995 ◽

Vol 23 (4) ◽

pp. 219-227 ◽

Cited By ~ 1

Author(s):

F M Pagliano ◽

G C Galbiati

Keyword(s):

Blood Pressure ◽

Adverse Event ◽

Vascular Disease ◽

Systolic Pressure ◽

Double Blind Study ◽

Efficacy And Safety ◽

Double Blind ◽

End Of Treatment ◽

Clinically Significant ◽

Efficacy Of Treatment

The efficacy and safety of two different regimens of dihydroergocristine, in the treatment of patients with chronic cerebro-vascular disease, were compared in this double-blind study. Forty out-patients, 11 males and 29 females, aged 55 – 80 years were randomly assigned to treatment with 6 or 20 mg dihydroergocristine, daily, for 3 months. The Sandoz Clinical Assessment for Geriatrics (SCAG) scale was used to assess the efficacy of treatment. Both doses induced a statistically significant improvement ( P < 0.01) in total SCAG scores after both 45 and 90 days of treatment. The higher dose produced a significantly greater improvement in total SCAG scores than did the lower dose after both 45 and 90 days. There were no statistically or clinically significant changes in any of the laboratory parameters after either treatment; neither were there any statistically significant changes in blood-pressure or pulse-rate except in the case of standing systolic pressure which decreased significantly ( P < 0.01) in the 20 mg group. The only adverse event reported was a case of mild gastric pain at the end of treatment with 20 mg dihydroergocristine.

Download Full-text